Vestnik dermatologii i venerologii
https://vestnikdv.ru/jour
Peer-rewieved medical journal
Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov
ru-RU
Vestnik dermatologii i venerologii
0042-4609
<p>Authors who publish with this journal agree to the following terms:</p> <ol> <li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under the <a href="https://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener">Creative Commons NonCommertial 4.0 International License</a> (CC BY-NC 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li>Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See <a href="http://opcit.eprints.org/oacitation-biblio.html" target="_new">The Effect of Open Access</a>).</li> </ol> <p>All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical '<em>Vestnik dermatologii i venerologii</em>'.</p> <div><details> <summary><strong>READ the details online</strong> (tap to see in details)</summary> <h4>Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical '<em>Vestnik dermatologii i venerologii</em>'</h4> <p><em>Russian Society of Dermatovenerologists and Cosmetologists</em>, represented by its president Alexey Kubanov and acting on the basis of the Charter (hereinafter referred to as the Publisher), on the one hand, offers an indefinite circle of persons (hereinafter referred to as the Author), and on the other hand, hereinafter jointly referred to as the parties, to execute this agreement (hereinafter referred to as the Agreement) on the publication of scientific materials (hereinafter referred to as the Article) in a scientific journal “<em>Vestnik dermatologii i venerologii</em>” (further-the Journal) in accordance with the conditions stated below.</p> <p>1. <strong>General Provisions</strong></p> <ul> <li>This Agreement, in accordance with clause 2 of Article 437 of the Civil Code of the Russian Federation, is a public offer (hereinafter referred to as the Offer) requiring full and unconditional acceptance (Acceptance), which, in accordance with Article 438 of the Civil Code of the Russian Federation, means the sending by the Author of his/her materials by way of uploading the same to the online electronic system designed to accept manuscripts for consideration, and subsequently posted in the corresponding section of the Journal’s website on the Internet information and telecommunications network (hereinafter referred to as the Internet).</li> <li>In accordance with the current legislation of the Russian Federation regarding the observance of copyright on electronic information resources, all materials found in the website, including submitted electronic journals, may not be reproduced in whole or in part in any form (electronic or printed) without the prior written consent of the Publisher. Prior consent can be given by publishing an article in the open access and expressing the appropriate permission, which is in the form of an open Creative Commons license in the designated section of the journal’s website (where the published materials are placed) on the Internet. The journal requires license users to reference the original source, i.e., the publication, if the Author permits use of the public materials in the context of other documents.</li> </ul> <p>2. <strong>Terms used in the Agreement</strong></p> <ul> <li>“Author” refers to an individual (or individuals) whose creative work has led to the creation of the manuscript of a scientific article.</li> <li>“Manuscript” of the article in the journal is the result of conducting fundamental and applied scientific research in the form of scientific material, review of a scientific material, a scientific report, a bibliographic review on certain topics of scientific research, and a historical reference devoted to figures of Russian and foreign science, which is then submitted by the author for publication in the journal.</li> <li>“Offer” is the document (an offer to the author) for the publication of an article by posting it on the journal’s website on the Internet.</li> <li>“Publication” is the placement of an article in the journal.</li> <li>“Article” is the manuscript of the article that has passed the reviewing, editorial and publishing process.</li> <li>“Acceptance of the offer” refers to the full and unconditional acceptance of the offer on the terms specified in paragraph 3 of this agreement (the author accepts offer by sending a Submission to the publisher, uploading the manuscript of the article, along with accompanying materials, to the online electronic system designed to accept articles for consideration, which is then posted in the corresponding section of the journal’s website on the Internet).</li> <li>“Journal” is a scientific peer-reviewed journal registered as a mass media entity in the Roskomnadzor register.</li> <li>“Submission” is an electronic appeal of the author to the publisher for the publication of an article in the journal by uploading the manuscript and accompanying materials to the online electronic system designated for accepting articles for consideration, and subsequently posting them in the corresponding section of the journal’s website on the Internet).</li> <li>“Publisher” refers to <em>Russian Society of Dermatovenerologists and Cosmetologists</em>, which is the founder and publisher of the journal. Article metadata includes the materials in Russian and English that are intended for inclusion in International Scientific Databases (ISD), namely the following:</li> <li>title of the article</li> <li>information about each of the authors (surname and first name; patronymic; place of work with the postal address indicated, contact information (e-mail), scan of identification card from the Ministry of Internal Affairs for each author</li> <li>abstract</li> <li>keywords</li> <li>thematic rubricator: UDC (Universal Decimal Classification) or other library and bibliographic classification and subject indexes</li> <li>bibliographic list (list of references).</li> <li>“Editorial board” is the creative team that prepares the journal for publication.</li> <li>“Editorial Council” is an advisory body under the editorial board of the journal.</li> <li>“Parties” refers to the author and the publisher.</li> <li>“Author Guidelines” are the requirements for materials published in the journal, posted in the authors section of the journal’s website on the Internet.</li> </ul> <p>3. <strong>Subject of the Agreement (Offer)</strong></p> <p>Under this agreement, the Author grants the Publisher, free of charge for the entire period of validity in accordance with the legislation of the Russian Federation, a non-exclusive license to use the Article created by the former for publication in the Journal, as well as the rights to use the article in the following ways:</p> <ul> <li>Reproduction of the Article or its sections or parts, as well as the metadata of the Article in Russian or other languages, in any material form, including on paper and electronic media, as a separate work in journals and/or databases (local or in the Internet) of the Publisher and/or other persons, at the discretion of the Publisher;</li> <li>Distribution of the Article or its sections or parts, as well as the metadata of the Article in Russian or other languages, on any medium. as part of the Journal and/or databases of the Publisher or other persons, at the discretion of the Publisher, or as an independent work around the world whether on Open-Access terms or for a fee without remuneration to the Author;</li> <li>Making the Article or any of its sections or parts, as well as the Article’s metadata in Russian or other languages, publicly available in such a way that any person can access the Article from any place, including via the Internet, and at any time of their own choosing;</li> <li>Granting permission/s for the use of the Article or its individual parts, as well as its metadata in Russian or other languages, to third parties with notice to the Author made by posting relevant information on the Journal’s website, without paying remuneration to the Author;</li> <li>Processing the Article, including by translating it to other languages, and by using the revised (translated) articles in the aforementioned ways. <ul> <li>Other rights not directly transferred to the Publisher under this Agreement, including patent rights to any process, method etc., described by the Author in the Article, as well as trademark rights, are reserved for the Author.</li> <li>The territory where the rights to the Article are allowed to be used is the whole world.</li> <li>The validity of this Agreement commences from the moment the Author sends a Submission to the Journal by uploading the manuscript of an Article and supplementary materials to the online electronic system designed to accept articles for consideration, and subsequently posted in the corresponding section of the Journal’s website on the Internet.</li> <li>The rights are granted by the Author to the Publisher free of charge; the publication of the Article in the Journal does not entail any financial deductions to the Author.</li> <li>If the Publisher decides to reject the Submission or refuse to publish the Article in the Journal, this Agreement becomes invalid. The decision to refuse publication will be sent to the Author at the e-mail address specified in the Submission.</li> <li>The Publisher undertakes to provide the Author with the necessary services related to the publication of the Article on the Journal’s website during the term of the agreement.</li> </ul> </li> </ul> <p>4. <strong>General Provisions of Rendering the Services</strong></p> <p>The Publisher will provide services to the Author only if the following conditions are met:</p> <ul> <li>The parties have concluded a corresponding service agreement.</li> <li>The Author has uploaded to the site all the materials necessary to enable the provision of services.</li> <li>The Author has paid for the services in full.</li> </ul> <p>Services are provided to the Author on a paid basis after executing the appropriate contracts (for Fast-track editorial evaluation of a manuscript and prior-to-schedule publication in case of its acceptance, for publication of the article in open access, etc.).</p> <p>If the materials are provided by the Author in violation of the guidelines and requirements of this offer, the Publisher reserves the right to reject the Submission and refuse to provide services if it has been found that the provided materials violate any of the guidelines and requirements of this offer.</p> <p>The Publisher will not be held responsible for the unauthorized use by third parties of the data provided by the Author during the term of the agreement.</p> <p>5. <strong>Rights and Duties of the Parties</strong></p> <p>The Author guarantees that:</p> <ul> <li>S/he holds the copyright the exclusive rights to the materials transferred as part of the manuscript of the Article.</li> <li>The rights granted to the Publisher under this agreement have not been previously transferred and will not be transferred to third parties in the future during the duration of the Agreement.</li> <li>The manuscript contains all references to the cited authors and/or publications (materials) provided for under the current copyright legislation.</li> <li>The Author has obtained all the necessary permissions for all information and other materials s/he holds no copyright to and that are used in the manuscript of the Article.</li> <li>The Article manuscript contains only materials permitted to be published in the open press in accordance with the current legislative acts of the Russian Federation, and its publication and distribution will not lead to the disclosure of secret (confidential) information (including state secrets).</li> <li>The Author has informed co-authors about the terms of this Agreement and has received their consent to execute this Agreement under the terms provided for in the Agreement. The Author carries certain obligations under the terms of the Agreement.</li> <li>S/he should submit the manuscript of the Article in accordance with the Author Guidelines listed on the Journal’s website;</li> <li>The author should not use an electronic copy of the Article for commercial purposes and in other journal publications without the consent of the Publisher;</li> <li>In the process of preparing a manuscript for publication, the Author is obligated to undertake the following: <ul> <li>Make corrections to the text of the manuscript that have been marked by the reviewers and accepted by the editorial board, and/or as necessary, upon the request of the Publisher and the editorial board, finalize the manuscript of the Article;</li> <li>Review and accept of reject the proofreading of the manuscript of the article under the terms stipulated by the publication schedule of the Journal;</li> <li>Make only the minimum of corrections to the proofreading of manuscript, which usually entails correcting and/or making factual and conjecture changes.</li> </ul> </li> </ul> <p>The Author has the following rights and duties:</p> <ul> <li>Use preprint or prior-to publication versions of an unpublished article in the form and content accepted by the Publisher for publication in the Journal. Such prior-to-publish versions can be placed as electronic files on the personal websites of the Author (co-authors) or on the protected external websites of the employers of the Author; however, the Author cannot use the unpublished version(s) for commercial sale or for systematic external distribution by a third party (i.e. post on social media). The author or co-authors must, in turn, carry out certain duties, namely: <ul> <li>Include the following warning in the prior-to-publish version: “This is prior-to-publish version of the article accepted for publication in (Journal’s name), ©, copyright (year), copyright owner specified in the Journal)”;</li> <li>Provide the corresponding electronic link to the Publisher’s website at <a href="https://vestnikdv.ru/">https://vestnikdv.ru/</a> and/or via the DOI.</li> </ul> </li> <li>Copy or transfer a copy of the published article in whole or in part to colleagues free of charge for their personal or professional use, for the promotion of academic or scientific research, or for informational purposes of the Author’s employer.</li> <li>Use materials from a published article in a book written by one of the co-authors.</li> <li>Use individual figures, tables and text excerpts from the Article for his or her (or co-authors’ own training purposes or to include them in other published works in printed or electronic format) by a third party, or to submit them in electronic format on an internal computer network or on the public website of the Author (co-authors) or his/her employer.</li> <li>Include the Article in educational collections for use in the classroom, either for free distribution to the Author’s (co-authors’) students or in electronic format on a local server for access by students as part of the training course, as well as for internal training programs at the institution of the Author’s employer.</li> </ul> <p>The Publisher, for its part, is obliged to:</p> <ul> <li>Publish the Author’s article in the Journal in printed and electronic form in accordance with the terms of this Agreement;</li> <li>If necessary as so decided by the Journal’s editorial board, provide the Author with the proofreading of the manuscript and make a reasonable edit of the Author’s work;</li> <li>Provide the Author with an electronic copy of the published Article to the Author’s e-mail address within 15 working days from the date of publication of the relevant Journal issue;</li> <li>Comply with the Author’s rights as provided for by the current legislation, as well as protect them and take all necessary measures to prevent copyright infringement by third parties.</li> </ul> <p>The Publisher has a right to:</p> <ul> <li>Carry out technical and literary editing of the Article manuscript without altering the main content;</li> <li>Conduct an expert evaluation of the manuscript and invite the Author to make the necessary changes, if any, of which until such time the article will not yet be published in the Journal;</li> <li>In any subsequent authorized use by the Author (and/or other persons) of the Journal and/or Article (including any separate part or fragment thereof), require that a link to the Journal, Publisher, Author or other copyright holders, the title of the Article, the Journal number, and the year of publication be specified in the Journal;</li> <li>Post preliminary and/or advertising information about the upcoming publication of the Article in the media and other information sources;</li> <li>Establish the guidelines for accepting and publishing materials in the Journal;</li> <li>Temporarily suspend the provision of services to the Author when technical, technological or other issues that prevent the smooth provision of such services are encountered, until such that the issues are eliminated;</li> <li>Make changes to the offer in accordance with the procedure established by the offer.</li> </ul> <p>The editorial board of the Journal, headed by the editor-in-chief, has the exclusive rights to select and/or reject materials sent to the Journal editorial office for publications purposes. The manuscript sent by the Author to the Journal editorial office is not subject to return. The editorial board of the Journal does not enter into correspondence about rejection of submissions.</p> <p>In all cases not stipulated and not provided for in this agreement, the parties are obliged to be guided by the relevant current laws of the Russian Federation.</p> <p>6. <strong>Acceptance of the Offer and Execution of the Agreement. Terms of the Agreement</strong></p> <ul> <li>This Agreement comes into force from the moment of its execution, when the Author accepts the offer by submitting the manuscript to the Publisher, and is valid for the duration of the exclusive rights to the Article.</li> <li>Acceptance of the offer by the author creates an Agreement in writing (Articles 438 and 1286.1 of the Civil Code of the Russian Federation) on the terms of the offer.</li> <li>Transfer of the exclusive right to an Article (alienated) by the Author to a third party, does not terminate this agreement.</li> </ul> <p>7. <strong>Procedure for changing and terminating the Agreement</strong></p> <ul> <li>The Publisher has the right to unilaterally change the terms of this Agreement, in advance, at least 10 (ten) calendar days before the entry into force of the intended relevant changes, but with notice to the Author through the Journal’s website or by e-mail to the Author’s e-mail address specified in the Author’s Submission. The changes will take effect from the date specified in the relevant notification.</li> <li>If the Author rejects the changes to the terms of this Agreement, s/he has the right to notify the Publisher by sending a written notification through the online electronic system designed for accepting articles for consideration, making sure that the same is posted in the corresponding section of the Journal’s website on the Internet, or to the official e-mail address of the editorial office on the Internet.</li> <li>This Agreement may be terminated prematurely, either by agreement of the parties at any time, or on other grounds provided for in this Agreement.</li> <li>The Author has the right to unilaterally withdraw from the execution of this Agreement by sending the Publisher a corresponding notification in writing at least 60 (sixty) calendar days in advance before the expected date of publication of the Article in the Journal.</li> <li>Termination of the Agreement for any reason does not release the parties from liability for any violation of the terms of the Agreement that occurred during the validity period.</li> </ul> <p>8. <strong>Responsibility</strong></p> <ul> <li>The parties are responsible for non-fulfillment or improper fulfillment of their obligations under the Agreement in accordance with the current relevant legislation of the Russian Federation.</li> <li>All information provided by the Author must be reliable. The Author is expected to provide accurate and complete the information to the Publisher. When using false information received from the Author, the Publisher is not responsible for the negative consequences caused by his actions on the basis of the false information provided.</li> <li>With regard to the content of the Article, the Author is solely responsible for compliance with the requirements of the laws of the Russian Federation pertaining to advertising, copyright and related rights’ protection, protection of trademarks and service marks, and the protection of consumer rights.</li> <li>The Publisher does not bear any responsibility under the agreement: <ul> <li>for any actions that are a direct or indirect result of Author’s illegal actions</li> <li>for any loss incurred by the Author, regardless of whether the Publisher could have foreseen the possibility of such losses or not.</li> </ul> </li> <li>The Publisher is released from liability for violation of the terms of the Agreement if such violation is caused by force majeure, including actions of state authorities (including the adoption of legal acts), fire, flood, earthquake, other natural disasters, lack of electricity and/or computer network failures, strikes, civil unrest, riots, etc.</li> </ul> <p>9. <strong>Dispute resolution</strong></p> <ul> <li>Disputes and disagreements will be resolved by the parties through negotiations, and in case of failure to reach an Agreement they will strive to seek resolution in accordance with the current legislation of the Russian Federation.</li> <li>If there are unresolved disagreements, the parties agree to resolve the disputes in court at the jurisdiction covered by the Publisher’s location in accordance with the current legislation of the Russian Federation.</li> </ul> <p>10. <strong>Miscellaneous</strong></p> <ul> <li>All notifications, messages, requests, etc. (with the exception of documents that must be sent as originals in accordance with the laws of the Russian Federation) are considered received by the Author if they were transmitted (sent) by the Publisher through the Journal’s website (including by publication), fax, e-mail based on the address specified in the Submission, and other communication channels. The parties recognize the legal force of notifications, messages, requests, etc., transmitted (sent) by the above methods.</li> <li>In the event of claims against the Publisher related to the violation of the exclusive copyright and other intellectual property rights of third parties when creating an article or in connection with the execution of this Agreement by the Author, as well as in connection with the use of the Article by the Publisher in accordance with the Agreement, the author undertakes: <ul> <li>To immediately take measures to resolve disputes with third parties soon after receiving Publisher’s notification, and if necessary, enter into legal proceedings on the Publisher’s side and take all appropriate actions needed to exclude the Publisher from the list of defendants;</li> <li>To reimburse the publisher for the legal costs incurred and expenses and losses caused by the application of measures to secure the claim and execute a court decision, and the money paid to a third party for the violation of exclusive copyright and other intellectual property rights, as well as other losses incurred by the Publisher in connection with the Author’s non-compliance with the guarantees provided by them under this Agreement.</li> </ul> </li> </ul> <p>11. <strong>Legal address and details of the Publisher</strong></p> <ul> <li>Russian Society of Dermatovenerologists and Cosmetologists</li> <li>Address: 3 bld 6, room 403, Korolenko street, 107076 Moscow, Russian Federation</li> <li>TIN: 7718162794; KPP: 771801001; OGRN: 1027739491361.</li> </ul> </details></div>
-
Analysis of the epidemiological situation and dynamics of the incidence of sexually transmitted infections in the Russian Federation over a ten-year period (2012–2022)
https://vestnikdv.ru/jour/article/view/16741
<p>Sexually transmitted infections (STIs) are socially significant diseases and require close attention due to the multifactorial causes that influence their spread. In 2012–2022, the Russian Federation maintained a downward trend in the incidence of STIs (from 267.6 to 91.3 cases per 100 thousand population), established since 1998 in all age groups. In 2022, compared to 2012, the incidence rates decreased: syphilis — by 42.7%; gonococcal infection — by 77.7%; trichomoniasis — by 75.8%; chlamydial infections — by 72.1%; anogenital herpetic infection — by 51.2%; anogenital (venereal) warts — by 36.5%. But at the same time, in 2021 and 2022, there was an increase in the incidence of syphilis and gonococcal infection: compared to 2019, the increase in the incidence of syphilis was 25.9%, and that of gonococcal infection — 5.2%. The increase in the incidence of syphilis was largely due to an increase in this indicator in the Central (from 18.1 to 37.3 cases per 100 thousand population) and Northwestern (from 14.5 to 16.2 cases per 100 thousand population) federal districts ( FO). An increase in the incidence of gonococcal infection in 2022 compared to 2019 was observed in the Central (+26.3%), Northwestern (+31.2%) and Ural (+27.6%) Federal Districts.</p>
Margarita R. Rakhmatulina
Elena Yu. Novoselova
Lidia E. Melekhina
Copyright (c) 2024 Rakhmatulina M.R., Novoselova E.Y., Melekhina L.E.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
8
23
10.25208/vdv16741
-
Deficient skin proteins rescue of expression in patients with epidermolysis bullosa: efficacy of gentamicin
https://vestnikdv.ru/jour/article/view/16737
<p>Epidermolysis bullosa is a group of rare hereditary skin diseases based on mutations in the genes of structural proteins of the epidermis and the dermal-epidermal junction. Clinically, epidermolysis bullosa is characterized by the appearance of erosions and blisters on the skin and mucous membranes in response to any minor impact. Currently, the treatment of epidermolysis bullosa is only symptomatic. Pathogenetic methods of the epidermolysis bullosa therapy are under development. One of the new possible pathogenetic directions in the treatment of epidermolysis bullosa is aminoglycoside antibiotics (gentamicin, geneticin, paromomycin). A number of studies have shown the ability of gentamicin to promote readthrough terminating codon and resume the synthesis of type VII collagen in keratinocytes and fibroblasts in patients with epidermolysis bullosa with nonsense mutations in the <em>COL7A1.</em> The review presented the possibilities of gentamicin therapy for patients with epidermolysis bullosa, describes the mechanism of its action, summarizes data from clinical trials.</p>
Olga G. Artamonova
Arfenya E. Karamova
Alexey A. Kubanov
Vadim V. Chikin
Ekaterina S. Monchakovskaya
Copyright (c) 2024 Artamonova O.G., Karamova A.E., Kubanov A.A., Chikin V.V., Monchakovskaya E.S.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
24
30
10.25208/vdv16737
-
Early diagnosis of skin oncologic diseases using artificial intelligence technologies
https://vestnikdv.ru/jour/article/view/16746
<p>The last decade has seen significant progress in computer-aided image analysis and recognition, with modern computer-aided diagnostic algorithms not only catching up with, but in many aspects surpassing human abilities. At the heart of this breakthrough is the development of deep convolutional neural networks, which have given a new impetus to medical diagnosis, particularly of skin cancers. In this paper, we analyzed photo-based skin disease classification systems developed using algorithms based on deep learning convolutional neural networks. Such methods have been variously reported to enable automated diagnosis of skin neoplasms with high sensitivity and specificity. A disease that requires more detailed analysis of graphic images — skin melanoma — was chosen as the main object of study. Early diagnosis of melanoma is of great socio-economic importance, as in this case the prognosis of patients is significantly improved. The aim of this work is to analyze the results of artificial intelligence (AI) applications in dermatology, especially in the context of early detection of skin melanoma. Scientific articles were searched in PubMed, Scopus and eLIBRARY databases using the keywords “convolutional neural networks”, “skin cancer” and “artificial intelligence”. The depth of the search was 10 years. The final analysis included 38 sources where the results of our own research were presented. The advantages of artificial intelligence methods for dermatologists were analyzed. Artificial intelligence can significantly assist dermatologists in developing visual neoplasm diagnosis skills and improve diagnostic accuracy. The use of AI to process dermatoscopic data in conjunction with the analysis of anamnestic and clinical information from medical records will reduce the burden on the healthcare system through correctly diagnosed benign skin tumors. All of this promises to have a significant impact on the future development of dermatovenerology.</p> <div id="gtx-trans" style="position: absolute; left: 2px; top: 659.637px;"> <div class="gtx-trans-icon"> </div> </div>
Simon О. Samokhin
Alexander V. Patrushev
Yulia I. Akaeva
Sergei A. Parfenov
Gennadii G. Kutelev
Copyright (c) 2024 Samokhin S.О., Patrushev A.V., Akaeva Y.I., Parfenov S.A., Kutelev G.G.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
38
46
10.25208/vdv16746
-
Langerhans cells and gamma delta Т-lymphocytes in the pathogenesis of psoriasis
https://vestnikdv.ru/jour/article/view/14875
<p>Psoriasis is a frequently occurring inflammatory skin disease. Fundamental research into the pathogenesis of psoriasis has significantly expanded our understanding of skin immunology, which has enabled the introduction of innovative and highly effective therapies. Psoriasis is a largely T-lymphocyte-mediated disease in which activation of innate immune cells and pathogenic T cells leads to inflammation and hyperproliferation of keratinocytes. Langerhans cells like dendritic cells (DCs), which play an important role in the immune system, are mainly distributed in the epidermis. Since human and mouse skin DC subpopulations share common ontogenetic characteristics, we can further investigate the role of DCs in psoriatic inflammation in mice. γδT cells are an unconventional population of T-lymphocytes that play an indispensable role in host defense, immune surveillance, and immune system homeostasis. Although γδT cells constitute only a small fraction of the total T cell pool, emerging evidence suggests that aberrantly activated γδT cells may play a role in the pathogenesis of psoriasis. Dermal γδT cells are the major IL-17-producing cells in the skin that respond to IL-23 stimulation. In addition, γδT cells have characteristics of memory cells that mediate repeated episodes of psoriatic inflammation. This review discusses the mechanisms by which Langerhans cells and γδT cells participate in the pathogenesis of psoriasis.</p>
Ekaterina V. Sorokina
Eugene O. Kalinichenko
Irina V. Bisheva
Vera N. Stolpnikova
Copyright (c) 2024 Sorokina E.V., Kalinichenko E.O., Bisheva I.V., Stolpnikova V.N.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
31
37
10.25208/vdv14875
-
Assessment of the quality of life in patients with onychomycosis and mycosis of the feet with concomitant non-alcoholic fatty liver disease against the background of complex therapy
https://vestnikdv.ru/jour/article/view/13731
<p><strong>Background. </strong>Сurrently, much attention is paid to the quality of patients, which is a promising direction of life, allowing to put a complete and objective picture of the disease, determine the most stable method of treatment, and evaluate its results.</p> <p><strong>Aims. </strong>To evaluate the effectiveness of complex therapy in patients with onychomycosis and mycosis of the feet with concomitant non-alcoholic severe liver disease (NAFLD) using a modified questionnaire-questionnaire of the combined index of quality of life (QL-Index).</p> <p><strong>Methods. </strong>The combined index of quality of life (QL-Index) was determined in patients with onychomycosis and mycosis of the feet with with concomitant NAFLD before and after complex therapy.</p> <p><strong>Results. </strong>Analysis of the results of assessing the presence of a combined index of quality of life in 117 patients with onychomycosis and foot mycosis with concomitant NAFLD before treatment showed that the presence of onychomycosis and mycosis of the feet in the majority of respondents has a strong impact on the lives of the respondents (69.2%). After the complex treatment, according to the results of the combined questionnaire-questionnaire of the quality of life index, it was revealed that social activity in patients with onychomycosis and foot mycosis with concomitant NAFLD increased, and the psycho-emotional state improved. The quality of life of patients has improved, which significantly increased the effectiveness of this complex treatment.</p> <p><strong>Conclusion. </strong>The high efficacy and safety of complex therapy, which included the use of the systemic antimycotic itraconazole in combination with external antifungal drugs, a hepatoprotector and a prebiotic in patients with onychomycosis and mycosis of the feet with concomitant NAFLD.</p>
Gulnaz R. Rustamkhanova
Zarema R. Hismatullina
Natalia A. Vlasova
Dinara T. Gashimova
Copyright (c) 2024 Rustamkhanova G.R., Hismatullina Z.R., Vlasova N.A., Gashimova D.T.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
47
55
10.25208/vdv13731
-
Experience with the fixed combination of benzoyl peroxide and clindamycin in acne therapy
https://vestnikdv.ru/jour/article/view/16050
<p><strong>Background</strong>. Acne is one of the most common dermatoses, affecting more than 9% of the world’s population. Acne negatively affects the patient’s quality of life and self-esteem, often leading to the development of anxiety and depression. The combination of pharmacological drugs with different mechanisms of action in one external dosage form can provide higher therapeutic efficacy.</p> <p><strong>Aims</strong>. To evaluate the effectiveness and tolerability of a combination drug with a fixed dose of clindamycin 1% and benzoyl peroxide 5% in the treatment of patients with mild to moderate papulopustular acne.</p> <p><strong>Methods</strong>. A single-center, open-label, observational, prospective study lasting 6 weeks was performed, which included 40 patients with mild to moderate papulopustular acne who received a gel with a fixed dose of clindamycin 1% and benzoyl peroxide 5% once a day. A clinical assessment of the effectiveness of therapy was carried out, PH, greasiness and moisture of the facial skin were measured, and the dynamics of the dermatological quality of life index was studied.</p> <p><strong>Results</strong>. The proportion of patients who showed significant improvement at the end of 6 weeks of treatment was 32/40 (80%). The total proportion of patients who showed significant and moderate improvement at the end of therapy reached 36/40 (90%).</p> <p><strong>Conclusion</strong>. The results obtained showed the high therapeutic effectiveness of the gel with a fixed dose of clindamycin 1% and benzoyl peroxide 5% in the treatment of mild to moderate papulopustular acne.</p>
Anna A. Verchoumova
Vladislav R. Khairutdinov
Igor N. Telichko
Copyright (c) 2024 Verchoumova A.A., Khairutdinov V.R., Telichko I.N.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
56
62
10.25208/vdv16050
-
Possibilities of using topical retinoids and azelaic acid in acne therapy
https://vestnikdv.ru/jour/article/view/11661
<p><strong>Background.</strong> Acne is a common, complex and multifactorial inflammatory disease that results from a variety of causes. Acne therapy is an urgent problem of dermatocosmetology. The clinical manifestations of dermatosis can be alleviated, and its long-term consequences can be prevented by early diagnosis and timely initiation of treatment, affecting multifaceted all parts of the pathogenesis.</p> <p><strong>Aims.</strong> To evaluate the clinical efficacy and safety of the use of monotherapy of 0.1% adapalene cream (Adaclean) with combined external therapy of 0.1% adapalene cream (Adaclean) with 20% azelaic acid cream (Azix-Derm) in the treatment of mild to moderate acne.</p> <p><strong>Methods.</strong> Under our supervision at the Department of Plastic Reconstructive Surgery, Cosmetology and Regenerative Medicine of the State Budgetary Educational Institution of Higher Professional Education Rost of the State Medical University of the Ministry of Health of Russia, the clinics “Ekaterininskaya” and “MIR-O-MED” there were 50 patients aged 12 to 50 years (18 (36%) men and 32 (64%) women) with mild and moderate acne. Patients with comedonal acne, in the absence of multiple inflammatory elements, which made up group 1 of observation (<em>n</em> = 16), were prescribed Adaclean cream, 1 time per day (evening) against the background of skin care. In the group with mild to moderate papulo-pustular acne and post-inflammatory changes (group 2, <em>n</em> = 34), patients were prescribed a combination of 0.1% adapalene cream and 20% azelaic acid cream (Adaclean (evening) and Azix-Derm (morning)). The follow-up period was 6 months.</p> <p><strong>Results. </strong>Total clinical remission after 6 months therapy was achieved in 70% of cases, a significant improvement — in 28%, improvement — in 2%. In patients with a comedonal form of acne against the background of monotherapy with Adaclean cream, clinical recovery was obtained in 44% of patients, a significant improvement — in 50%, and an improvement — in 6%. In patients from the group of papulo-pustular acne of mild to moderate severity, after 3 months the use of complex therapy Adaclean and Azix-Derm noted almost complete relief of the inflammatory process; after 6 months therapy clinical recovery was recorded in 58%, significant improvement — in 36%; 6% showed partial improvement, which is associated with irregular use of drugs and skin care products. After 6 months combined treatment was able to achieve regression of dyschromia in 18–46% of patients, atrophic scars — in 5–22%, which significantly improved the results of therapy and made it possible to achieve a good cosmetic effect.</p> <p><strong>Conclusion.</strong> The combined use of drugs for external use of adapalene (Adaclean) and AK (Azix-Derm) in the treatment of papulo-pustular acne of mild and AK (Azix-Derm) in the treatment of papulo-pustular acne of mild and moderate severity can significantly increase the effectiveness of treatment, achieve a stable clinical effect and remission of the disease, as well as improve the quality of life of patients.</p>
Olga A. Katkhanova
Galina N. Burtseva
Anastasia V. Solovyova
Copyright (c) 2024 Katkhanova O.A., Burtseva G.N., Solovyova A.V.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
63
72
10.25208/vdv11661
-
Hyperhidrosis: problems and solutions
https://vestnikdv.ru/jour/article/view/11878
<p>The functional role of sweating is not limited only to thermoregulation and excretion. There are other functions of it — the ability to enhance and maintain hydration and barrier function of the skin. Excessive sweating can lead to an exacerbation or cause many skin diseases, form psychological discomfort in a person due to wet clothes or an accompanying unpleasant odor. Primary hyperhidrosis may be an autosomal dominant genetic disease. Secondary, usually generalized hyperhidrosis is often associated with drug effects on the body or a systemic disease. The following approaches are used in the treatment of hyperhidrosis: 1) blocking the release of sweat to the skin surface (aluminum salts and formaldehyde); 2) physiotherapy (iontophoresis); 3) destruction of sweat glands and cessation of sweat production (excision of a skin flap with subcutaneous fat, curettage, microwave technology, etc.); 4) termination of the signal from the central nervous system to the sweat glands (transthoracic endoscopic sympathectomy, percutaneous radiofrequency sympathectomy, botulinum toxin injections, systemic anticholinergic drugs). External remedies for excessive sweating include the Russian drug Formagel®, containing 3.7% formaldehyde. This drug is a non-invasive, easily doable, effective, safe method of treating hyperhidrosis.</p>
Stanislava Yu. Petrova
Vera I. Albanova
Konstantin S. Guzev
Copyright (c) 2024 Petrova S.Y., Albanova V.I., Guzev K.S.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
73
84
10.25208/vdv11878
-
Difficult path to the diagnosis of chromomycosis
https://vestnikdv.ru/jour/article/view/13276
<p>Chromomycosis is a slowly occurring mycosis of subcutaneous adipose tissue and skin. Most often, cases of the disease are recorded in countries with a tropical and subtropical climate. In the Russian Federation, the disease occurs sporadically. Very rarely (2 cases out of 100) malignant transformation into squamous cell carcinoma occurs. The article presents a clinical case of chromomycosis. A description is given of a patient in whom squamous cell carcinoma was detected at the onset of the disease, which was the reason for treatment by oncologists. Six months later, the patient had a relapse in the area of the postoperative scar and a focus in the area of the right hand. Repeated biopsy with histological examination made it possible to establish the correct diagnosis. Interest in the above clinical case was caused by the detection of chromomycosis in a resident of the city of Saint Petersburg, who was not in endemic areas, was not engaged in agricultural work, and denied the primary injury. Our patient experienced a rapid malignancy of the focus, after surgical treatment, a recurrence of deep mycosis occurred. A good effect was obtained from systemic antimycotic therapy.</p>
Tatyana V. Melnikova
Natalya Yu. Burtseva
Tatyana A. Cheboksarova
Evgeny V. Sokolovskiy
Copyright (c) 2024 Melnikova T.V., Burtseva N.Y., Cheboksarova T.A., Sokolovskiy E.V.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
85
92
10.25208/vdv13276
-
Anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis
https://vestnikdv.ru/jour/article/view/15341
<p>Clinical observations of three patients aged 26, 43 and 37 years with severe psoriasis and psoriatic arthritis are presented. Clinical examples show the experience of effective treatment of patients with psoriasis and psoriatic arthritis using anti-cytokine therapy with an interleukin-17 inhibitor, initiated when the disease progresses. The clinical picture of the presented observations was characterized by an aggressive course of the skin and articular process, torpidity to basic therapy, despite the young age of the patients. It has been shown that the early termination of the progression of the inflammatory process in psoriasis with the use of genetically engineered biological therapy with secukinumab leads to a decrease in symptoms, both on the part of the skin and manifestations of the disease on the part of the musculoskeletal system. The high efficacy and safety of the drug allow complete control of the disease and improve the quality of life in patients suffering from severe forms of dermatosis.</p>
Julia S. Kovaleva
Igor V. Kazantsev
Annetta A. Aibazova
Ekaterina O. Ovchinnikova
Anastasia A. Garina
Anastasia P. Shabaldina
Copyright (c) 2024 Kovaleva J.S., Kazantsev I.V., Aibazova A.A., Ovchinnikova E.O., Garina A.A., Shabaldina A.P.
https://creativecommons.org/licenses/by-nc/4.0
2024-03-18
2024-03-18
100 1
93
103
10.25208/vdv15341